A synthetic peptide built on the Semax / ACTH(4-10) backbone with modifications intended to extend stability; discussed for cognition and neuroprotection — but with almost no evidence of its own.
Research use only. No approvals anywhere, and no dedicated human trials.
Also known as: N-Acetyl-Semax adamantane analog
Adamax is proposed to act like its parent Semax: modulating melanocortin receptors and, most importantly, upregulating the neurotrophic factors BDNF and NGF with enhanced TrkB receptor signalling, plus dopaminergic and serotonergic modulation. An N-acetyl group and a C-terminal adamantane are intended to slow enzymatic breakdown and extend half-life relative to Semax. Every one of these mechanistic claims is inferred from Semax pharmacology rather than demonstrated for Adamax itself.
Being blunt: there is essentially no independent peer-reviewed clinical or dedicated preclinical literature on Adamax. Its supporting evidence is really Semax's — in rodents a single intranasal dose of Semax raised hippocampal BDNF protein roughly 1.4-fold and BDNF mRNA about 3-fold, increased TrkB phosphorylation and reduced ischemic infarct volume. Semax is approved in Russia for ischemic stroke and cognitive impairment; that status does not transfer to Adamax.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Essentially uncharacterised — no formal human safety studies exist for Adamax. Risks are presumed low by analogy to Semax, but that is an assumption, not a finding, and is complicated by a longer half-life and no purity oversight in research-chemical supply.
Semax — the parent compound and the far better-evidenced alternative on the same BDNF/TrkB pathway. Selank — commonly paired in nootropic discussion; a tuftsin-derived peptide targeting anxiety and GABA-ergic tone.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Closest to Semax and N-Acetyl-Semax. Adamax is a stability-optimised Semax analog with a longer claimed half-life, but with far less direct evidence than Semax — which itself leans heavily on Russian data.
Not meaningfully. Direct human trials are lacking; the rationale is borrowed from Semax research.
It adds an N-terminal acetyl group and a C-terminal adamantane moiety, intended to extend half-life and stability.
Yes. A longer half-life with no safety characterisation means the unknowns are larger, not smaller, than for the parent compound.
No reviews yet. If you've used Adamax, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.